Hersh EM - Search Results

1

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. Hersh EM, et al. Invest New Drugs. 2011 Jun;29(3):489-98. doi: 10.1007/s10637-009-9376-8. Epub 2010 Jan 16. Invest New Drugs. 2011. PMID: 20082117 Clinical Trial.

2

Ipilimumab pharmacotherapy in patients with metastatic melanoma.

Jeter JM, Cranmer LD, Hersh EM. Jeter JM, et al. Among authors: hersh em. Clin Med Insights Oncol. 2012;6:275-86. doi: 10.4137/CMO.S7245. Epub 2012 Jul 30. Clin Med Insights Oncol. 2012. PMID: 22904648 Free PMC article.

3

A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.

Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R. Hersh EM, et al. Cancer. 2010 Jan 1;116(1):155-63. doi: 10.1002/cncr.24720. Cancer. 2010. PMID: 19877111 Free article. Clinical Trial.

4

Phase I/II study of ipilimumab for patients with metastatic melanoma.

Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Weber JS, et al. J Clin Oncol. 2008 Dec 20;26(36):5950-6. doi: 10.1200/JCO.2008.16.1927. Epub 2008 Nov 17. J Clin Oncol. 2008. PMID: 19018089 Clinical Trial.

5

The role of the CTLA4 blockade in the treatment of malignant melanoma.

Cranmer LD, Hersh E. Cranmer LD, et al. Cancer Invest. 2007 Oct;25(7):613-31. doi: 10.1080/07357900701522315. Cancer Invest. 2007. PMID: 18027152 Review.

6

Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.

O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS. O'Day SJ, et al. Among authors: hersh em. J Clin Oncol. 2009 Dec 20;27(36):6207-12. doi: 10.1200/JCO.2008.20.3075. Epub 2009 Nov 16. J Clin Oncol. 2009. PMID: 19917850 Clinical Trial.

7

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG; Oblimersen Melanoma Study Group. Bedikian AY, et al. Among authors: hersh em. J Clin Oncol. 2006 Oct 10;24(29):4738-45. doi: 10.1200/JCO.2006.06.0483. Epub 2006 Sep 11. J Clin Oncol. 2006. PMID: 16966688 Clinical Trial.

8

Phase I trial of imexon in patients with advanced malignancy.

Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R. Dragovich T, et al. J Clin Oncol. 2007 May 1;25(13):1779-84. doi: 10.1200/JCO.2006.08.9672. J Clin Oncol. 2007. PMID: 17470869 Clinical Trial.

9

A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.

Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E. Weber JS, et al. Cancer. 2010 Aug 1;116(15):3683-91. doi: 10.1002/cncr.25119. Cancer. 2010. PMID: 20564083 Free article. Clinical Trial.

10

A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.

Ebbinghaus S, Rubin E, Hersh E, Cranmer LD, Bonate PL, Fram RJ, Jekunen A, Weitman S, Hammond LA. Ebbinghaus S, et al. Clin Cancer Res. 2005 Nov 1;11(21):7807-16. doi: 10.1158/1078-0432.CCR-05-0909. Clin Cancer Res. 2005. PMID: 16278403 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

450 results

Search Page